Form D · Biotechnology
RheumaGen, Inc.
Denver, CO · CIK 0001942974
Offering snapshot reported Apr 17, 2024 · SEC filing
- Reported sold
- $4.91M Offering amount: $15M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 17, 2024 | Initial | $4,906,587 | No comparison | 3 | SEC filing |
| Apr 17, 2024 | Initial | $700,000 | No comparison | 1 | SEC filing |
| May 26, 2023 | Initial | $300,000 | No comparison | 1 | SEC filing |
| Oct 18, 2022 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-510836
Source: Form D, filed Apr 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregory L. Andrews | Director |
| Thomas Fratacci | Director |
| Brian Matthew Freed | Executive |
| Richard Anthony Freed, Iii | Director, Executive |
| Bruce Michael Goodwin | Director |
| Ryan Kane Hart | Executive |
| James Brian Hart, Jr. | Executive |
| Bobak Robert Mozayeni | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Quebec St. Bldg. 600, Ste. 205
Denver, CO, 80230
Denver, CO, 80230